Fda Approves Astrazeneca Ovarian Cancer Drug

The U.S. Food and Drug Administration approved the first drug to treat cases of ovarian cancer linked to specific genetic mutations.

BING NEWS:
  • AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
    The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
    04/25/2024 - 7:35 am | View Link
  • AstraZeneca profit up on strong sales of cancer drugs
    British pharmaceutical giant AstraZeneca on Thursday said net profit jumped 21 percent in the first three months of the year thanks to strong growth in sales of cancer drugs.
    04/24/2024 - 8:41 pm | View Link
  • Enhertu Gets FDA Accelerated Approval for Unresectable, Metastatic HER2-Positive Solid Tumors
    The approval of AstraZeneca’s and Daiichi Sankyo's Enhertu ... open-label trial included patients with endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other cancer types with ...
    04/8/2024 - 2:13 am | View Link
  • US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
    The drug, sold under the brand name Enhertu, originally won US approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients, and the fresh approval opens the treatment ...
    04/5/2024 - 4:20 pm | View Link
  • US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
    HER2 is a protein that stimulates quick growth of cancer cells ... endometrial, ovarian and pancreatic cancers, according to AstraZeneca. The drug showed clinically meaningful survival benefits ...
    04/5/2024 - 10:38 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News